Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Miricorilant in MASH
NCT07553663Phase 1Completed
- Sponsor
- Corcept Therapeutics
- Start
- Apr 2026
- Primary completion
- Sep 2026
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of miricorilant in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Corcept Therapeutics. Primary endpoint: Pharmacokinetics. Started Apr 2026; status: completed.
02
Drugs
miricorilant
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT07553663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07553663.